Retatrutide: The Honest Guide to Safety, the Underground Version, and What to Do

If you have been reading about retatrutide, you have probably seen two things: astonishing weight-loss numbers, and people quietly buying it online right now. Both are real. This guide is the honest version. It explains what retatrutide is, what the trial actually showed, why you cannot yet get it from a pharmacy, and what the grey-market route really costs you in risk. No hype, no lecture.

What retatrutide actually is

Retatrutide is the newest weight-loss molecule, and in trials so far it is the most powerful of them. In plain terms it is a "triple agonist," which means it switches on three different receptors in the body at once: GIP, GLP-1, and glucagon. A receptor is simply a docking point on your cells that, when activated, changes how your body handles hunger, blood sugar, and energy.

The older medicines pull fewer of these levers. Semaglutide (the ingredient in Wegovy) acts on one, GLP-1. Tirzepatide (the ingredient in Mounjaro) acts on two, GIP and GLP-1. Retatrutide adds the third, glucagon, which also nudges the body to burn more energy. More levers, in the trials so far, has meant more weight lost. We compare the three head to head in Retatrutide vs Mounjaro vs Wegovy, so this guide stays focused on the honest safety picture instead.

What the evidence really shows

According to data published in the New England Journal of Medicine (via PubMed), a phase 2 trial by Jastreboff and colleagues in 2023 followed 338 adults for 48 weeks. The results were striking. Average body-weight loss was 24.2% at the 12 mg dose and 22.8% at the 8 mg dose, meaning people lost close to a quarter of their starting weight, compared with just 2.1% on placebo (a dummy injection with no active drug). At the 12 mg dose, 83% of people lost 15% or more of their body weight, which is roughly a seventh of everything they weighed.

The side effects were mostly gastrointestinal, meaning nausea and similar gut symptoms. They were dose-related, which means they tended to be worse at higher doses, and mostly mild to moderate. They were also eased by starting at a lower dose and building up slowly. The trial also recorded a dose-dependent rise in heart rate, meaning the heart beat somewhat faster at higher doses, and this peaked at around 24 weeks. It is worth knowing this trial was funded by Eli Lilly, the company developing the drug. You can read the study here: https://doi.org/10.1056/NEJMoa2301972.

The bigger news: the first phase 3 results are in

Phase 2 was only the opening chapter. In May 2026, Eli Lilly reported the first results from TRIUMPH-1, the large phase 3 trial, and they were even stronger. TRIUMPH-1 followed roughly 2,339 adults with obesity, and without diabetes, for 80 weeks. At the highest dose, people lost an average of about 28% of their body weight, more than a quarter of everything they weighed, compared with roughly 4% on placebo. Close to half of them, about 45%, lost 30% or more of their body weight, a level of loss that until recently was mostly seen after weight-loss surgery. In an extension for people who started heavier, average loss reached about 30% by 104 weeks, which is two years. Every dose tested met the trial's main goals and improved cardiometabolic risk markers such as blood pressure and blood sugar.

An early meta-analysis that pooled the trials available at the time (Lopez and colleagues, Journal of the Endocrine Society, 2024, via PubMed) pointed in the same direction, reporting substantial weight loss and a meaningful drop in average blood sugar (HbA1c). The authors rated the certainty of that evidence as low to moderate, simply because the drug was still early in testing then. You can read it here: https://doi.org/10.1210/jendso/bvae163.

Important: retatrutide is still investigational

Here is the part the headlines skip. Even with those strong phase 3 results, retatrutide is still investigational, which means it is a drug being studied, not yet a finished, approved medicine. Positive trial results are the step that comes before approval, not approval itself. The company still has to complete its full phase 3 program and submit the data to the regulators, who then decide. As of now it is not yet approved by the EMA (the European Medicines Agency), the Spanish AEMPS (the national medicines agency), or the FDA (the United States regulator), and it is not yet available in licensed pharmacies anywhere. In short, no legitimate doctor can hand you a pharmacy box of retatrutide today, because it does not exist yet.

The grey-market reality, told straight

Because it is not approved, the only retatrutide circulating right now comes from unregulated sources. It is sold as a "research chemical" through underground suppliers, and it is a genuinely different thing from a pharmacy medicine. We are not here to moralize about it, we are here to tell you plainly what you are taking on.

• Unknown purity. You cannot know how much active drug is really in the vial, or how much is something else.
• Wrong or contaminated contents. What is on the label may not be what is inside, and there is no independent check.
• Non-sterile vials. A product you inject should be sterile. Grey-market vials carry no such guarantee, which is an infection risk.
• Guesswork dosing. There is no verified concentration and no dosing schedule from a clinician, so people are estimating.
• Zero medical monitoring. No one is watching your heart rate, your gut side effects, your nutrition, or your muscle loss.

Put simply, using grey-market retatrutide is a gamble with an unregulated product. You are betting your health on a vial no one has verified.

Where we stand

We do not sell, source, or prescribe underground or grey-market retatrutide. We provide honest information and medical oversight. Once a pharmaceutical-grade, approved version is available in licensed pharmacies, our double board-certified specialist will be able to prescribe and supervise it properly.

Why supervision will matter, even for the approved version

When retatrutide is finally approved, it will still be a powerful drug, and how it is used will matter as much as whether it works. Proper supervision is not paperwork, it is what keeps the result healthy. A doctor-led approach focuses on the things a vial and a video cannot manage for you:

• Protecting your muscle while you lose fat. Fast weight loss can strip muscle along with fat, so treatment is paired with resistance training and enough protein to hold on to it. We cover this in detail in GLP-1 Weight Loss and Muscle Loss.
• Managing the gut side effects. Starting low, going slow, and adjusting the dose is how the nausea is kept mild instead of miserable.
• Monitoring heart rate and cardiovascular health. Because the trial showed a rise in heart rate, this is something to measure and watch, not ignore.
• Integrating it with existing hormone therapy. For men already on testosterone therapy (TRT), retatrutide needs to fit sensibly into the protocol you are already on, not collide with it.

For the two approved medicines you can actually be prescribed today, see Mounjaro and Wegovy: How Safe and How Effective Are They?